December 12, 2005
Phase 1 Clinical Data Demonstrates Gemin X Compound GX15-070 is Well-Tolerated and Generates Biological and Clinical Improvements in CLL
Results from Preclinical Studies of Gemin X's GX15-070 Presented in Four Posters at American Society of Hematology Annual Meeting
August 8, 2005
Timothy Barberich and Wayne Roe to join Gemin X Board of Directors
May 19, 2005
Gemin X Biotechnologies Secures U.S. $65.2 Million in Financing
January 6, 2005
Gemin X Biotechnologies Initiates Phase 1/2 Clinical Trial with GX15-070 in Chronic Lymphocytic Leukemia
